Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
irinotecan/прострация
Линкът е запазен в клипборда
Страница 1 от 336 резултата
Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
The prevention of post-chemotherapy symptoms such as delayed emesis, anorexia, and fatigue induced by irinotecan has not been studied. We compared the effects of dexamethasone (Dex) with those of a placebo on these symptoms in a randomized study. Seventy patients scheduled to receive irinotecan
[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
The combination of irinotecan-bevacizumab is effective in patients with glioblastoma relapse but fatigue is a commonly reported side effect. The objective of this study was to evaluate the level and evolution of fatigue in a series of patients treated with therapeutic
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND
In the current Phase II study, the authors evaluated the association between genomic polymorphic variants in uridine diphosphate glucuronosyl transferase (UGT1A1), methylenetetrahydrofolate reductase (MTHFR), and thymidylate synthase (TS) genes, and the incidence of the adverse effects of
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
This meta-analysis was performed to compare the effects and toxicities between irinotecan/platinum (IP) and etoposide/platinum (EP) regimens as the fist-line treatment of patients with extensive-stage small cell lung cancer (E-SCLC). A systematic search was made of MEDLINE, Cochrane, ISI Web of
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
To assess the rate of R(0) resection of liver metastases achieved after chemotherapy with FOLFIRINOX.
METHODS
Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0)
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies.
METHODS
Thirty patients with metastatic or locally advanced (unresectable or recurrent)
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
Cyclooxygenase-2 (COX-2) has been shown to be expressed in a variety of tumors including pancreatic cancer. The combination of gemcitabine and irinotecan is active in pancreatic cancer. The purpose of this study is to determine the toxicity and response rate to the addition of the
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL-305 and established the maximum tolerated dose and recommended phase II dose (RP2D).
METHODS
In a standard 3 + 3 design, IHL-305 was administered IV on day 1 of a
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
To assess the efficacy of irinotecan (CPT-11) in the treatment of advanced colorectal cancer in both chemotherapy-naive and pretreated patients.
METHODS
Two hundred thirteen patients (aged 18 to 75 years) with metastatic colorectal cancer, World Health Organization (WHO) performance status
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Preclinical activity of irinotecan has been seen in glioma models, but only modest efficacy has been noted in clinical studies, perhaps related to drug distribution and/or pharmacokinetic limitations. In preclinical testing, irinotecan liposome injection (nal-IRI) results in prolongation of drug
Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
Preclinical findings suggest that adding targeted therapies to combination radiation-chemotherapy can enhance treatment efficacy; however, this approach may enhance normal tissue toxicity. We investigated the maximum tolerated dose, dose-limiting toxicities, and response rate when the
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2/VEGFR-3), platelet-derived growth factor receptor beta, and c-Kit in combination with capecitabine and
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE
This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively.
METHODS
Forty-eight (median age 54 years, range 26-77 year)
Най-пълната база данни за лечебни билки, подкрепена от науката
- Работи на 55 езика
- Билкови лекове, подкрепени от науката
- Разпознаване на билки по изображение
- Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
- Прочетете научни публикации, свързани с вашето търсене
- Търсете лечебни билки по техните ефекти
- Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите
Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания
